About Inflammatory Bowel Disease
Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn's disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss. Inflammatory bowel disease can also prove to be life-threatening for the patients. Ulcerative colitis generally affects the colon, where inflammation and ulcers develop in the innermost lining of the colon and the rectum of a patient. Crohn's disease causes inflammation of the lining of the GI tract. The inflammation in Crohn's disease affects various areas of the GI tract such as the large intestine and small intestine, or both. Inflammatory bowel disease is a chronic medical condition, which has no permanent cure and demands a lifetime of treatment and management. The preferred treatment options include anti-inflammatory steroidal products and immuno-suppressive agents such as the TNF-α inhibitors.
TechNavio's analysts forecast the Global Inflammatory Bowel Disease market to grow at a CAGR of 3.95 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis.
On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments.
Technavio Announces the Publication of its Research Report – Global Inflammatory Bowel Disease Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Inflammatory Bowel Disease Market 2015-2019: AbbVie Inc., Biogen Idec Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Shire plc and UCB SA.
Other Prominent Vendors in the market are: Amgen, Akebia Therapeutics, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals, Galapagos, Genentech, Mitsubishi Tanabe, Novartis, Novo Nordisk, Pfizer and Salix Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period. This leads to a rise in the number of treatment-seeking patients, which increases the overall consumption of medicines.”
According to the report, the high prevalence of inflammatory bowel disease among the population resulting in a rise in the number of treatment-seeking patients has led to increased consumption of medications, thereby having a positive impact on the market share of the vendors.
Further, the report states the high cost of drugs used to treat patients suffering from inflammatory bowel disease is one of the major challenges hindering the growth of the market.
AbbVie Inc., Biogen Idec Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Shire plc and UCB SA., Amgen, Akebia Therapeutics, Boehringer Ingelheim, Celltrion, ChemoCentryx, Ferring Pharmaceuticals, Galapagos, Genentech, Mitsubishi Tanabe, Novartis, Novo Nordisk, Pfizer and Salix Pharmaceuticals
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook